PTC Therapeutics, Inc. (PTCT)

Market Cap	1.69B
Revenue (ttm)	818.73M
Net Income (ttm)	-618.05M
Shares Out	75.35M
EPS (ttm)	-8.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	767,748
Open	22.96
Previous Close	22.66
Day's Range	22.22 - 23.37
52-Week Range	22.03 - 59.84
Beta	0.37
Analysts	Hold
Price Target	39.77 (+77.47%)
Earnings Date	Oct 26, 2023

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic A...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2013
• Employees: 1,402
• Stock Exchange: NASDAQ
• Ticker Symbol: PTCT

Financial Performance

In 2022, PTCT's revenue was $698.80 million, an increase of 29.75% compared to the previous year's $538.59 million. Losses were -$559.02 million, 6.70% more than in 2021.

Analyst Forecast

According to 14 analysts, the average rating for PTCT stock is "Hold." The 12-month stock price forecast is $39.77, which is an increase of 77.47% from the latest price.

Price Target

$39.77

(77.47% upside)

Analyst Consensus: Hold